Advertisement

Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F–FDG PET/CT in pediatric patients with neuroblastoma

  • Chao Li
  • Jian Zhang
  • Suyun Chen
  • Shuo Huang
  • Shuqi Wu
  • Linlin Zhang
  • Fengxian Zhang
  • Hui Wang
Original Article

Abstract

Purpose

To evaluate the prognostic value of metabolic parameters and bone marrow uptake (BMU) patterns on pretherapeutic 18-F-fluorodeoxyglucose (18F–FDG) positron emission tomography/computed tomography (PET/CT) in pediatric patients with neuroblastoma (NB).

Patients and methods

Forty-seven pediatric patients with newly diagnosed neuroblastoma who underwent 18F–FDG PET/CT were retrospectively reviewed. Clinicopathological factors and metabolic parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and bone marrow uptake patterns on PET/CT were compared to predict recurrence-free survival (RFS) and overall survival (OS) by univariate and multivariate analysis.

Results

During the follow-up period, 27 (57.4%) patients experienced recurrence. MTV (P = 0.001), TLG (P = 0.004) and BMU patterns (P = 0.025) remained significant predictive factors for tumor recurrence, along with tumor size, histology, stage, lactate dehydrogenase (LDH) and other distant metastasis (except bone metastasis). Univariate analysis showed that histology, stage, tumor size (>37.25 cm), other distant metastasis, MTV (>88.10cm3) and TLG (>1045.2 g) and BMU patterns correlated with both RFS and OS (P < 0.05). On multivariate analysis, TLG remained the only independent prognostic factor for RFS (P = 0.016) and OS (P = 0.012), and BMU patterns and MTV were statistically significant for OS (P = 0.024 and P = 0.038, respectively).

Conclusion

Pretherapeutic 18F-FDG PET/CT can provide reliable prognostic information for neuroblastoma pediatric patients, and patients with high MTV, TLG and focal bone marrow (unifocal and multifocal) uptake on PET/CT may have inferior outcomes during subsequent treatment.

Keywords

Neuroblastoma Pet/ct Metabolic tumor volume Total lesion glycolysis Bone marrow involvement 

Notes

Funding

On behalf of all authors, the corresponding author states that no funding was received for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma Lancet. 2007;369(9579):2106–20.  https://doi.org/10.1016/S0140-6736(07)60983-0.CrossRefPubMedGoogle Scholar
  2. 2.
    Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24(1):65–86.  https://doi.org/10.1016/j.hoc.2009.11.011.CrossRefPubMedGoogle Scholar
  3. 3.
    Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in european children (1978-1997): report from the automated childhood cancer information system project. Eur J Cancer. 2006;42(13):2081–91.  https://doi.org/10.1016/j.ejca.2006.05.008.CrossRefPubMedGoogle Scholar
  4. 4.
    Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–16.  https://doi.org/10.1038/nrc1014.CrossRefPubMedGoogle Scholar
  5. 5.
    Brodeur GM, Fong CT, Morita M, Griffith R, Hayes FA, Seeger RC. Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human neuroblastomas. Prog Clin Biol Res. 1988;271:3–15.PubMedGoogle Scholar
  6. 6.
    Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D’Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6(12):1874–81.  https://doi.org/10.1200/JCO.1988.6.12.1874.CrossRefPubMedGoogle Scholar
  7. 7.
    Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.  https://doi.org/10.1056/NEJMra0804577.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cheung NK, Ostrovnaya I, Kuk D, Cheung IY. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol. 2015;33(7):755–63.  https://doi.org/10.1200/JCO.2014.57.6777.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer. 2011;47(8):1193–202.  https://doi.org/10.1016/j.ejca.2011.02.003.CrossRefPubMedGoogle Scholar
  11. 11.
    Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a european HR-NBL1/SIOPEN study. J Clin Oncol. 2014;32(10):1074–83.  https://doi.org/10.1200/JCO.2013.53.3604.CrossRefPubMedGoogle Scholar
  12. 12.
    Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. The Cochrane database of systematic reviews. 2015;9:CD009263.  https://doi.org/10.1002/14651858.CD009263.pub2.Google Scholar
  13. 13.
    Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol. 2001;19(14):3397–405.  https://doi.org/10.1200/JCO.2001.19.14.3397.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu CJ, Lu MY, Liu YL, Ko CL, Ko KY, Tzen KY, et al. Risk stratification of Pediatric patients with Neuroblastoma using volumetric parameters of 18F-FDG and 18F-DOPA PET/CT. Clin Nucl Med. 2017;42(3):e142–e8.  https://doi.org/10.1097/RLU.0000000000001529.CrossRefPubMedGoogle Scholar
  15. 15.
    Papathanasiou ND, Gaze MN, Sullivan K, Aldridge M, Waddington W, Almuhaideb A, et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med. 2011;52(4):519–25.  https://doi.org/10.2967/jnumed.110.083303.CrossRefPubMedGoogle Scholar
  16. 16.
    Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237–43.  https://doi.org/10.2967/jnumed.108.060467.CrossRefPubMedGoogle Scholar
  17. 17.
    Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54(8):1202–8.  https://doi.org/10.2967/jnumed.112.116426.CrossRefPubMedGoogle Scholar
  18. 18.
    Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative (1)(8)F-FDG PET/CT in patients with pancreatic cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014;55(6):898–904.  https://doi.org/10.2967/jnumed.113.131847.CrossRefGoogle Scholar
  19. 19.
    Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(6):925–35.  https://doi.org/10.1007/s00259-011-2059-7.CrossRefPubMedGoogle Scholar
  20. 20.
    Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med. 2013;54(7):1032–8.  https://doi.org/10.2967/jnumed.112.116053.CrossRefPubMedGoogle Scholar
  21. 21.
    Choi ES, Ha SG, Kim HS, Ha JH, Paeng JC, Han I. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging. 2013;40(12):1836–42.  https://doi.org/10.1007/s00259-013-2511-y.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol. 2010;96(3):302–7.  https://doi.org/10.1016/j.radonc.2010.07.003.CrossRefPubMedGoogle Scholar
  23. 23.
    Maffione AM, Ferretti A, Grassetto G, Bellan E, Capirci C, Chondrogiannis S, et al. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40(6):853–64.  https://doi.org/10.1007/s00259-013-2357-3.CrossRefPubMedGoogle Scholar
  24. 24.
    Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, et al. Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin lymphoma: results from an international collaborative study. J Nucl Med. 2017;  https://doi.org/10.2967/jnumed.116.184218.
  25. 25.
    Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau A, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging. 2009;36(11):1813–21.  https://doi.org/10.1007/s00259-009-1183-0.CrossRefPubMedGoogle Scholar
  26. 26.
    Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(12):2436–46.  https://doi.org/10.1007/s00259-010-1545-7.CrossRefPubMedGoogle Scholar
  27. 27.
    Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243–57.  https://doi.org/10.1148/radiol.11101352.CrossRefPubMedGoogle Scholar
  28. 28.
    Choi YJ, Hwang HS, Kim HJ, Jeong YH, Cho A, Lee JH, et al. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. Ann Nucl Med. 2014;28(4):304–13.  https://doi.org/10.1007/s12149-014-0813-1.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Chao Li
    • 1
  • Jian Zhang
    • 1
    • 2
  • Suyun Chen
    • 1
  • Shuo Huang
    • 1
  • Shuqi Wu
    • 1
  • Linlin Zhang
    • 1
  • Fengxian Zhang
    • 1
  • Hui Wang
    • 1
  1. 1.Department of Nuclear Medicine, Xinhua HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Shanghai Universal Medical Imaging Diagnostic CenterShanghaiChina

Personalised recommendations